infectious disease diagnostics News
-
Visby Medical Appoints Everett Cunningham to Board of Directors
Visby Medical™, a leading medical diagnostic company, today announced Everett Cunningham has been appointed to the company’s Board of Directors. Cunningham is currently Chief Commercial Officer at Exact Sciences and brings 30 years of commercial experience in pharmaceuticals and molecular diagnostics to the company’s board. “I am thrilled to welcome Everett to the Visby ...
-
Visby Medical Appoints Terri S. Bresenham and Scott Edward Mendel to Board of Directors
Visby Medical™, a leading medical diagnostic company, today announced Terri Bresenham and Scott Mendel have been appointed to the company’s Board of Directors. Bresenham was most recently chief innovation officer at General Electric Corporation and Mendel was chief executive officer of GenMark Diagnostics. Together they bring over 45 cumulative years of experience in the medical ...
-
Alveo Technologies Expands Scientific Advisory Board with Appointment of Esteemed Healthcare Business Executive, Fran Soistman
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Fran Soistman has joined the company’s Scientific Advisory Board (SAB). Soistman is an accomplished business executive who has decades of experience driving profitable growth for healthcare entities. As a member of ...
-
How We Achieved the BioFire “Big 5”
Most infections present as a syndrome, with signs and symptoms that are common to many pathogens. Traditional diagnostic methods often rely on guesswork—ordering a targeted test for the most probable cause of illness, waiting hours or even days for results, and repeating the process until a pathogen is positively identified. The syndromic approach, however, empowers healthcare ...
-
Former Genmark Senior Vice President Scott O’Brien Joins Specific Diagnostics as Chief Commercial Officer
Specific Diagnostics today announced the appointment of Scott O’Brien as its Chief Commercial Officer. Mr. O’Brien is an industry veteran with over 20 years in molecular and infectious disease diagnostics, the last 10 at GenMark where he held a range of commercial positions, most recently Senior Vice President Global Marketing and International Sales at GenMark Diagnostics, ...
-
Specific Diagnostics Announces that David Barreca, former GenMark Sales Leader, Joins Specific as
Specific Diagnostics today announced the appointment of David Barreca as Vice President of US Sales. David was a key member of GenMark’s sales leadership team, most recently a Senior Director managing a team of Account Executives that drove growth of the GenMark infectious disease diagnostics product, contributing the sales growth that led to GenMark’s acquisition by Roche Diagnostics ...
-
Specific Diagnostics announces that Nathan Clark, former GenMark Sales Leader, joins Specific Diagnostics as Strategic Account Director, US East
Specific Diagnostics today announced the appointment of Nathan Clark as Strategic Account Director. Nathan was a key member of the GenMark sales leadership team, most recently as a sales manager for GenMark’s Northeast region, overseeing a team of 7 sales professionals and infectious disease specialists responsible for approximately $70M of revenue. Nathan was a critical part of the sales ...
-
NanoPin Technologies Announce a Strategic Collaboration with Shanghai Reigncom Biotechnology to Bring Novel Infectious Disease Diagnostic Products to the China Market
NanoPin Technologies (New Orleans, Louisiana, USA) announces the establishment of a strategic partnership with Shanghai Reigncom Biotechnology Co., Ltd. (Shanghai, China). NanoPin and Reigncom will work together to commercialize NanoPin’s high-sensitivity and high-specificity infectious disease detection technology on Reigncom's RZ-500 ultra-high performance liquid chromatography tandem ...
-
ECCMID 2020 Alert: Selux Diagnostics Hosting Integrated Symposium at 30th European Congress of Clinical Microbiology & Infectious Diseases
Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat superbug infections and combat antimicrobial resistance, today announced it will host an integrated symposium on aspects that impact antimicrobial resistance, rapid diagnostics and clinical care at this spring's 2020 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Paris, France. ...
-
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted
April 25, 2022 at 9:30 AM EDT NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 25, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office (“US PTO”) has granted the patent regarding ...
-
As Companies Work Around the Clock to Address COVID-19, BIO Outlines Key Policy Priorities to Prevent the Next Pandemic
The Senate Committee on Health, Education, Labor and Pensions, chaired by Senator Lamar Alexander, will hold an important hearing today to examine lessons learned from the current global health crisis to help make sure we are better prepared for the next pandemic. Public health expert and patient advocate, Dr. Julie Gerberding, will join the discussion, alongside former top policy leaders. The ...
-
Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety
As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduced CC50/IC50 Assay service with a high level of assay sensitivity and accuracy. The CC50 and IC50 will be plotted using a sigmoidal dose-response curve, and the selectivity index (SI) for each compound is estimated by dividing the CC50 with the IC50. Pharmaceutical ...
-
NEC OncoImmunity AS and Oslo University Hospital team up to develop a diagnostic for COVID-19 using artificial intelligence
NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awarded a prestigious grant from the Research Council of Norway (RCN) to develop an artificial intelligence (AI) platform that will enable the rapid design of T-cell diagnostics for emerging or endemic infectious diseases. The project will ...
-
NanoPin Technologies Founder`s Study Demonstrates Greater Accuracy in Detecting TB in Infants
NanoPin Technologies Inc, a biotechnology company focused on developing advanced diagnostics to improve the lives of millions of individuals affected by infectious diseases worldwide, announced the release of a scientific study conducted by founder Tony Hu, Ph.D. Dr. Hu is a professor and Weatherhead Presidential Chair in Biotechnology Innovation at the Tulane University School of Medicine. ...
-
Alveo Technologies Awarded Grant for its be.well™ COVID-19 Test
Alveo Technologies, today announced it has been awarded a grant to improve upon the performance and usability of its testing platform, and if successful, to advance the development and scale manufacturing of the company’s be.well™ COVID-19 test from the Bill & Melinda Gates Foundation. As the first of its kind platform, be.well™ is as accurate as a PCR test with all the ...
-
Roswell Biotechnologies and Imec to Develop First Molecular Electronics Biosensor Chips for Infectious Disease Surveillance, Precision Medicine and DNA Storage
Roswell Biotechnologies, Inc., the leader in molecular electronics sensor chips, and imec, a world-leading research and innovation hub in nanoelectronics and digital technologies, announced today a partnership to develop the first commercially available molecular electronics biosensor chips. These chips are the brains behind Roswell Technologies' powerful new platform for DNA sequencing, to ...
-
D-Kimia expands to further support North American Market
D-Kimia Diagnostic Solutions announces the opening of its offices in New York to support its growing partnerships with US diagnostic labs and further develop its companion testing solutions with major anti-viral treatments. Hepatitis C (HCV) affects an estimated 5 million Americans and there is a growing concern of a much larger undiagnosed population. The CDC now recommends all baby boomers ...
By D-Kimia, LLC
-
Alveo Technologies Expands Leadership Team with Appointment of Julianne Averill as Chief Financial Officer
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced it has appointed Julianne Averill, CPA, as Chief Financial Officer. In this role, Ms. Averill will be responsible for leading all financial operations and implementing key business strategies to accelerate Alveo’s growth as the ...
-
Vela Diagnostics Announces Development of New Test Kit for Detection of Wuhan Coronavirus
Vela Diagnostics has announced the development of the ViroKey SA201 2019-nCoV RT-PCR Test, a new test kit for the detection of the 2019 Novel Coronavirus (2019-nCoV), otherwise known as the Wuhan Coronavirus. The Wuhan Coronavirus was first identified in mid-December 2019 in Wuhan, China. Human-to-human transmission has been confirmed by China’s health ministry. According to Chinese health ...
-
Vela Diagnostics Submitting Novel Coronavirus Diagnostic Test to FDA for Emergency Use Authorization (UPDATE)
Vela Diagnostics has developed the ViroKey SA201 SARS-CoV-2 RT-PCR Test, a new diagnostic test for the detection of COVID-19. Vela Diagnostics is currently in discussions with the U.S. Food and Drug Administration (FDA) for authorization of the test under the emergency use authorization (EUA). The EUA will allow the emergency use of FDA medical products in qualified labs, thereby facilitating ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you